EpiPen

Pharmalot Ed Silverman

Hospitals are itching for a share of the Mylan settlement over Medicaid rebates

Pharmalot Ed Silverman

West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Valeant looks to sell Salix to lessen debt load

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement

Pharmalot Ed Silverman

An EpiPen alternative is about to return to your local pharmacy

Pharmalot Ed Silverman

STAT Plus: EpiPen prescriptions continue to climb, but market share dropped

Pharmalot Ed Silverman

Elizabeth Warren criticizes feds for a ‘shamefully weak’ deal with Mylan

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

The Pharmalot View Ed Silverman

STAT Plus: Health officials should reject latest gambit by EpiPen maker to feed at the public trough

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens

Pharmalot Ed Silverman

Mylan to pay $465 million to settle claims of shortchanging Medicaid

Pharmalot Ed Silverman

STAT Plus: Mylan overcharged Medicaid for EpiPen for years, despite warnings

First Opinion Jennifer Brokaw

Cheap EpiPen alternative risks patients’ lives. I’ve seen it myself

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers

Pharmalot Ed Silverman

STAT Plus: Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war